Loss Contingency, Claims Settled, Number Of Companies

No definition available.

Name:	mrk_LossContingencyClaimsSettledNumberOfCompanies
Namespace Prefix:	mrk_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Loss Contingency, Companies Settled With, Minimum Number

+ References

No definition available.

+ Details

Name:	mrk_LossContingencyCompaniesSettledWithMinimumNumber
Namespace Prefix:	mrk_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Loss Contingency, Joint Stipulation Response Period

+ References

No definition available.

+ Details

Name:	mrk_LossContingencyJointStipulationResponsePeriod
Namespace Prefix:	mrk_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

- Definition

Loss Contingency, Number Of Cases Remanded

+ References

No definition available.

+ Details

Name:	mrk_LossContingencyNumberOfCasesRemanded
Namespace Prefix:	mrk_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number Of Plaintiffs In Complaint

+ References

No definition available.

+ Details

Name:	mrk_NumberOfPlaintiffsInComplaint
Namespace Prefix:	mrk_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Patent Extension, Term

+ References

No definition available.

+ Details

Name:	mrk_PatentExtensionTerm
Namespace Prefix:	mrk_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Pediatric Exclusivity, Term

+ References

No definition available.

+ Details

Name:	mrk_PediatricExclusivityTerm
Namespace Prefix:	mrk_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_LitigationReserve
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-9

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 720
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483359/720-20-50-1

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 27
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482395/460-10-55-27

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482425/460-10-50-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-1

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of another entity's patents that the entity has allegedly infringed.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

+ Details

Name:	us-gaap_LossContingencyPatentsAllegedlyInfringedNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of pending claims pertaining to a loss contingency.

+ References

+ Details

Name:	us-gaap_LossContingencyPendingClaimsNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_ValuationAllowancesAndReservesTypeAxis=mrk_LegalDefenseCostsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=mrk_PGRPetitionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mrk_Dr.SchollsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationStatusAxis=mrk_MotionForSummaryJudgementGrantedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mrk_ZetiaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mrk_BridionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=us-gaap_PatentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mrk_JanuviaJanumetJanumetXRMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mrk_KeytrudaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mrk_SubcutaneousPembrolizumabMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=mrk_PGRPetitionProcessIneligibleToBeChallengedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Contingencies (Details) $ in Millions				1 Months Ended		6 Months Ended
Contingencies (Details) $ in Millions	Apr. 24, 2025 patent	Mar. 13, 2025	Apr. 13, 2023 patent	Dec. 31, 2023 case	Jun. 30, 2023	Jun. 30, 2025 USD ($) company case proceeding	Jun. 02, 2025 patent	May 01, 2025 plaintiff	Apr. 07, 2025	Mar. 21, 2025 plaintiff	Mar. 11, 2025 case	Dec. 31, 2024 USD ($)
Loss Contingencies [Line Items]
Number of plaintiffs in complaint \| plaintiff								6,000,000		7,000,000
Loss contingency, joint stipulation response period									14 days
Legal Defense Costs
Loss Contingencies [Line Items]
Legal defense costs reserve \| $						$ 255						$ 225
Pending Litigation \| Patents - PGR Petition
Loss Contingencies [Line Items]
Loss contingency, number of patents allegedly infringed	12
Dr. Scholl's \| U.S. \| Pending Litigation
Loss Contingencies [Line Items]
Loss contingency, pending claims \| case						575
Gardasil/Gardasil 9 \| U.S. \| Pending Litigation
Loss Contingencies [Line Items]
Loss contingency, pending claims \| case						125
Gardasil/Gardasil 9 \| U.S. \| Motion for Summary Judgement Granted
Loss Contingencies [Line Items]
Loss contingency, pending claims \| case											16
Gardasil/Gardasil 9 \| Non-US \| Pending Litigation
Loss Contingencies [Line Items]
Loss contingency, pending claims \| case						15
Zetia \| U.S. \| Pending Litigation
Loss Contingencies [Line Items]
Loss contingency, number of cases remanded \| case				4,000,000
Bridion \| Patents
Loss Contingencies [Line Items]
Loss contingency, claims settled, number of companies \| company						5
Bridion \| Settled Litigation \| Patents
Loss Contingencies [Line Items]
Patent extension, term		5 years			5 years
Pediatric exclusivity, term		6 months
Januvia, Janumet, Janumet XR \| Settled Litigation
Loss Contingencies [Line Items]
Loss contingency, companies settled with, minimum number \| company						24
Keytruda \| Pending Litigation \| Patents
Loss Contingencies [Line Items]
Loss contingency, pending claims \| proceeding						8
Loss contingency, number of patents allegedly infringed			9
Subcutaneous Pembrolizumab \| Pending Litigation \| Patents
Loss Contingencies [Line Items]
Loss contingency, pending claims							10
Loss contingency, number of patents allegedly infringed	15
Subcutaneous Pembrolizumab \| Pending Litigation \| Patents - PGR Petition
Loss Contingencies [Line Items]
Loss contingency, pending claims							3
Subcutaneous Pembrolizumab \| Pending Litigation \| PGR Petition Process, Ineligible to be Challenged
Loss Contingencies [Line Items]
Loss contingency, pending claims	3